Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | Cr |
| Molecular Weight | 51.9961 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cr]
InChI
InChIKey=VYZAMTAEIAYCRO-UHFFFAOYSA-N
InChI=1S/Cr
Nearly 60 years ago, chromium, as the trivalent ion, was proposed to be an essential element, but the results of new studies indicate that chromium currently can only be considered pharmacologically active and not an essential element. Chromium is a mineral that humans need in very small quantities. Good sources include broccoli, liver, and brewers' yeast. Taking chromium by mouth is effective for preventing chromium deficiency. It is also taken by mouth for depression, Turner's syndrome, polycystic ovary syndrome (PCOS), lowering "bad" cholesterol, raising "good" cholesterol in people taking heart medications called beta blockers, obesity, metabolic syndrome, heart attack, schizophrenia, bipolar disorder, binge eating disorder, and a disease called reactive hypoglycemia. Chromium has been marketed as an agent to reduce body mass and develop muscle; however, such marketing claims are no longer allowed in the United States because they are not supported by experiments. Trivalent chromium has also been proposed as a therapeutic agent to increase insulin sensitivity and affect lipid metabolism. Although effective in certain rodent models, beneficial effects in humans have not been unequivocally established.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The effects of chromium complex and level on glucose metabolism and memory acquisition in rats fed high-fat diet. | 2011-11 |
|
| Evaluation of insulin binding and signaling activity of newly synthesized chromium(III) complexes in vitro. | 2011-04-08 |
|
| Chromium (VI) inhibits mouse metallothionein-I gene transcription by modifying the transcription potential of the co-activator p300. | 2011-04 |
|
| Comparison of gene expression profiles in chromate transformed BEAS-2B cells. | 2011-03-18 |
|
| Cardioprotective effects of selenium on chromium (VI)-induced toxicity in female rats. | 2011-03 |
|
| Chromium improves production and alters metabolism of early lactation cows in summer. | 2011-02 |
|
| Chromium (D-phenylalanine)3 alleviates high fat-induced insulin resistance and lipid abnormalities. | 2011-01 |
|
| Simultaneous analysis of the local and systemic immune responses in mice to study the occupational asthma mechanisms induced by chromium and platinum. | 2010-11-09 |
|
| Chromium improves protein deposition through regulating the mRNA levels of IGF-1, IGF-1R, and Ub in rat skeletal muscle cells. | 2010-11 |
|
| Chromium attenuates high-fat diet-induced nonalcoholic fatty liver disease in KK/HlJ mice. | 2010-07-02 |
|
| Polo-like kinase 1 enhances survival and mutagenesis after genotoxic stress in normal cells through cell cycle checkpoint bypass. | 2010-05 |
|
| Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. | 2010-05 |
|
| Maternal dietary chromium restriction programs muscle development and function in the rat offspring. | 2010-03 |
|
| Chronic maternal dietary chromium restriction modulates visceral adiposity: probable underlying mechanisms. | 2010-01 |
|
| Effect of chromium supplementation on the diabetes induced-oxidative stress in liver and brain of adult rats. | 2009-12 |
|
| Chromium supplement inhibits skeletal muscle atrophy in hindlimb-suspended mice. | 2009-12 |
|
| Multiple metals predict prolactin and thyrotropin (TSH) levels in men. | 2009-10 |
|
| Trivalent chromium activates Rac-1 and Src and induces switch in the cell death mode in human dermal fibroblasts. | 2009-08-10 |
|
| Combined effects of niacin and chromium treatment on vascular endothelial dysfunction in hyperlipidemic rats. | 2009-07 |
|
| Chromium(III) induces oxidative stress in goldfish liver and kidney. | 2009-06-04 |
|
| Response to chronic exposure to hexavalent chromium in human monocytes. | 2009-06 |
|
| Chromium supplementation enhances insulin signalling in skeletal muscle of obese KK/HlJ diabetic mice. | 2009-04 |
|
| Effects of niacin and chromium on the expression of ATP-binding cassette transporter A1 and apolipoprotein A-1 genes in HepG2 cells. | 2009-04 |
|
| Protective effects of combined micronutrients on islet beta-cells of streptozotocin-induced diabetic mice. | 2009-03 |
|
| Niacin bound chromium treatment induces myocardial Glut-4 translocation and caveolar interaction via Akt, AMPK and eNOS phosphorylation in streptozotocin induced diabetic rats after ischemia-reperfusion injury. | 2009-01 |
|
| The effects of feeding with different levels of zinc and chromium on plasma thiobarbituric acid reactive substances and antioxidant enzymes in rats. | 2009 |
|
| Chromium (D-phenylalanine)3 supplementation alters glucose disposal, insulin signaling, and glucose transporter-4 membrane translocation in insulin-resistant mice. | 2008-10 |
|
| Chromium-mediated apoptosis: involvement of DNA-dependent protein kinase (DNA-PK) and differential induction of p53 target genes. | 2008-09-01 |
|
| Arsenite and cadmium, but not chromium, induce NAD(P)H:quinone oxidoreductase 1 through transcriptional mechanisms, in spite of post-transcriptional modifications. | 2008-08 |
|
| Effects of supplemental chromium on interferon-gamma (IFN-gamma) mRNA expression in response to Newcastle disease vaccine in broiler chicken. | 2008-08 |
|
| Blood pressure lowering effects of niacin-bound chromium(III) (NBC) in sucrose-fed rats: renin-angiotensin system. | 2008-07 |
|
| Chromium (VI) induces insulin resistance in 3T3-L1 adipocytes through elevated reactive oxygen species generation. | 2008-06 |
|
| Deposition of nickel, chromium, and cobalt on the skin in some occupations - assessment by acid wipe sampling. | 2008-06 |
|
| Gene expression profiles in rainbow trout, Onchorynchus mykiss, exposed to a simple chemical mixture. | 2008-03 |
|
| Hypersensitivity to chromium-induced DNA damage correlates with constitutive deregulation of upstream p53 kinases in p21-/- HCT116 colon cancer cells. | 2008-02-01 |
|
| Cholesterol efflux and the effect of combined treatment with niacin and chromium on aorta of hyperlipidemic rat. | 2008-01 |
|
| Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium. | 2008-01 |
|
| A role for transforming growth factor-beta apoptotic signaling pathway in liver injury induced by ingestion of water contaminated with high levels of Cr(VI). | 2007-10-15 |
|
| Chromium cross-links histone deacetylase 1-DNA methyltransferase 1 complexes to chromatin, inhibiting histone-remodeling marks critical for transcriptional activation. | 2007-10 |
|
| Characterization and distribution of the selected metals in the scalp hair of cancer patients in comparison with normal donors. | 2007-09 |
|
| Effect of chromium on carbohydrate and lipid metabolism in a rat model of type 2 diabetes mellitus: the fat-fed, streptozotocin-treated rat. | 2007-09 |
|
| Food chromium content, dietary chromium intake and related biological variables in French free-living elderly. | 2007-08 |
|
| Classification of heavy-metal toxicity by human DNA microarray analysis. | 2007-05-15 |
|
| Combination of chromium and biotin improves coronary risk factors in hypercholesterolemic type 2 diabetes mellitus: a placebo-controlled, double-blind randomized clinical trial. | 2007 |
|
| Effect of dietary chromium on resistance artery function and nitric oxide signaling in the sucrose-fed spontaneously hypertensive rat. | 2007 |
|
| Cytogenetic effects of a mixture of selected metals following subchronic exposure through drinking water in male rats. | 2006-12 |
|
| Transcriptome of the subcutaneous adipose tissue in response to oral supplementation of type 2 Leprdb obese diabetic mice with niacin-bound chromium. | 2006-11-27 |
|
| High-dose chromium(III) supplementation has no effects on body mass and composition while altering plasma hormone and triglycerides concentrations. | 2006-10 |
|
| Multivariate analysis of the selected metals in the hair of cerebral palsy patients versus controls. | 2006 |
|
| In vivo nephrotoxicity induced in mice by chromium(VI). Involvement of glutathione and chromium(V). | 1991-10 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/npc/chromium.html
Curator's Comment: Chromium is also used intravenously (by IV) as a supplement in nutritional IV drips. https://www.webmd.com/vitamins/ai/ingredientmono-932/chromium
The currently accepted value for chromium dietary intake is 25 mcg/day for women and 35 mcg/day for men. Daily dosages used in clinical trials for periods of up to 9 months range as follows: brewer's yeast up to 400 mcg/day; chromium chloride 50 to 600 mcg/day; chromium nicotinate 200 to 800 mcg/day; chromium picolinate 60 to 1,000 mcg/day. The potential for genotoxic effects exists at higher dosages.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 581
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 586
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 583
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 578
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
NCI_THESAURUS |
C637
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 590
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 588
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 579
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 584
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 580
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
NCI_THESAURUS |
C896
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 582
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 589
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 585
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
NDF-RT |
N0000185508
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 591
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 587
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID3031022
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
2496
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | RxNorm | ||
|
N0000171131
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | Allergens [Chemical/Ingredient] | ||
|
C370
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
0R0008Q3JB
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
m3505
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | Merck Index | ||
|
910
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
100000090349
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
28073
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
N0000184306
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | Cell-mediated Immunity [PE] | ||
|
DB11136
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
SUB13362MIG
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
D002857
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
0R0008Q3JB
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
231-157-5
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
23976
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
N0000175629
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | Increased Histamine Release [PE] | ||
|
7440-47-3
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)